MannKind reported $306.33M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
Adma Biologics USD 238.57M 238.54M Jun/2025
Dynavax Technologies USD 117.23M 117.11M Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Halozyme Therapeutics USD 117.62M 117.5M Jun/2025
Insmed USD 211.11M 209.29M Jun/2025
MacroGenics USD 63.21M 62.58M Jun/2025
MannKind USD 306.33M 303.29M Jun/2025
Merck USD 1.79B 0 Mar/2025
Novo Nordisk DKK 446M 0 Mar/2025
Pfizer USD 5.68B 5.2B Jun/2025
Sanofi 1.22B 36.5M Jun/2025
Xencor USD 71.3M 70.58M Jun/2025